AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 51 min read$UTHR

ROTHBLATT MARTINE A sold $647K of UTHR

ROTHBLATT MARTINE A (Chairperson & CEO) sold 1,186 shares of UNITED THERAPEUTICS Corp (UTHR) at $545.18 ($0.65M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Jun 5, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

Insider selling can influence short-term sentiment, but 10b5-1 plans generally reduce interpretability as a forward-looking bearish signal.

02

Market read

A routine 10b5-1 insider sale by UTHR leadership; likely limited trading impact absent other catalysts.

03

What to watch

Insider sales can be scheduled and tax-driven; without accompanying buys, guidance changes, or trial/approval news, the signal is weak.

Relevance 6/10Novelty 3/10Timing: Filed 2026-06-05; sale executed 2026-06-04

Background

The article is an SEC Form 4 insider transaction disclosure (open-market sale) for United Therapeutics.

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

SEC Form 4 shows UTHR CEO/Chair Martine Rothblatt sold 1,186 shares for ~$646.6K under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless paired with other news.

Evidence & confidence

The filing is a routine 10b5-1 open-market sale by an insider, providing a datapoint on trading activity rather than company performance.

Market effects

Sector

Minimal; insider sale in a single large biotech does not reset sector fundamentals.

Regional

None expected beyond UTHR-specific sentiment.

Global

None.

Counterpoint

What could challenge this read

Because it’s a pre-arranged 10b5-1 plan, the sale may reflect liquidity/portfolio management rather than bearish expectations.

Key entities

  • issuer
    United Therapeutics Corp

    Subject of the SEC Form 4 insider transaction disclosure.

  • insider
    Martine A. Rothblatt

    Chairperson & CEO who executed the reported sale under a pre-arranged 10b5-1 plan.

Read at source← All news

Related articles

AUG 5
$UTHRMed

UNITED THERAPEUTICS ($UTHR) Releases Q2 2026 Earnings

United Therapeutics (UTHR) reported Q2 2026 earnings of $7.27 per share, above the $6.97 estimate. Revenue was $783.3 million, below the $821.8 million estimate. The article also cites insider sales totaling 1,373 trades over six months, and notes a median analyst price target of $660.

quiverquant.com4 min
AUG 5
$UTHRMed

UNITED THERAPEUTICS Corp (UTHR): Results of Operations and Financial Condition

UNITED THERAPEUTICS Corp (UTHR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 uthrq22026-ex991.htm EX-99.1 Document Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Second Quarter 2026 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., August 5, 2026: United Therapeutics Corporation (Nasdaq: UTHR ), a

SEC EDGAR 8-K7 min